Christopher E. Loh

Christopher E. Loh


Partner, New York

Chris Loh practices general intellectual property law with an emphasis on biotechnology and Hatch-Waxman pharmaceutical patent litigation. He has litigated patent cases involving such diverse technologies as anticonvulsants, antisense probes, cholesterol-lowering statins, calcium-channel blockers and vascular stents. He also has significant experience in drafting licensing agreements, preparing noninfringement and freedom-to-operate opinions, and advising clients on complex intellectual property transactions.

Chris frequently writes articles for the National Law Journal, Bloomberg IP and Lexology.

While in law school, Chris served as Notes Editor for the Columbia Business Law Review and interned at the New York Volunteer Lawyers for the Arts, counseling clients on copyright, trademark and artist rights issues.

Case Highlight
Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc. and Mylan Inc.
D.N.J. (2011)

Led a team to victory on summary judgment against Mylan Pharmaceuticals on their invalidity allegations against patents relating to Lescol®.

Representative Matters
  • Novartis Pharmaceuticals Corp. against multiple defendants in cases concerning patents for Novartis’s Alzheimer’s Disease treatment Exelon® Patch (rivastigmine).
  • Novartis AG against Teva Pharmaceuticals USA, Inc. in a case concerning patents for Novartis’s transplant rejection therapy Myfortic® (mycophenolic acid).
  • Genzyme Corporation against multiple defendants in cases concerning patents for Genzyme’s renal disease treatment Hectorol® (doxercalciferol).
  • Novartis Pharmaceuticals Corp. against Mylan Pharmaceuticals, Inc. in a case concerning patents for Novartis’s statin drug Lescol® (fluvastatin).
  • Adams Respiratory Therapeutics, Inc. against Mutual Pharmaceutical Co., Inc. in a case concerning patents for Adams’s antitussive drug Mucinex® (guaifenisen).
  • AstraZeneca Pharmaceuticals LP against multiple defendants in cases concerning patents for AstraZeneca’s anticonvulsive and antidepressant medication Seroquel® (quetiapine).
  • IBM Corp. against Sky Technologies Inc. in a case concerning patents for Sky’s automated negotiation software.
  • Novartis Pharmaceuticals Corp. against Dr. Reddy’s Laboratories, Ltd. in a case concerning patents for Novartis’s antifungal treatment Lamisil® (terbinafine).
  • Bausch & Lomb Inc. against Allergan Inc. in a case concerning patents for Allergan’s glaucoma drug Alphagan® (brimonidine).
  • AstraZeneca AB against Mutual Pharmaceutical Co., Inc. in a case concerning patents for AstraZeneca’s antihypertensive medication Plendil® (felodipine).
Events / Publications